All infliximab biosimilars are classified as therapeutically equivalent and interchangeable for the FDA-approved indications. The most economical biosimilar product will be utilized based on cost and reimbursements at the time.

For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents 

 

---

Formulary, Restricted:

• Administration should be deferred to the outpatient settings. inFLIXimab may be used in the outpatient medical departments.
• Inpatient exception - rare situations where inFLIXimab would be given pre-surgery for cases of ulcerative colitis or Crohn's disease, or long-term patient who has not responded to other options.
• inFLIXimab is approved for use in the treatment of Kawasaki Disease in inpatient and outpatient.
• inFLIXimab is approved for inpatient use in the treatment of steroid refractory immunotherapy-induced colitis in inpatient and outpatient.

Dose Rounding: For inFLIXimab product, round dose nearest 50 mg for patients 18 years and over.

 

---

Reviewed: March 28, 2006, 28 March 2017 (Inflectra), 24 July 2018 (Renflexis), Feb. 2022 (Avsola), and Dec 2025 (Ixifi)             

Infliximab-qbtx (IXIFI) Spotlight.pdf

 

Updated: Febuary 26, 2013 (Dose Rounding), 27 Feb 2018 (Kawasaki Disease), 26 June 2018 (steroid refractory immunotherapy-induced colitis), August 2020 (infliximab biosimilars approved for pediatric ulcerative colitis)

---

Drug Alert: Inflectra Medication Guide

Drug Alert: Remicade Medication Guide

Drug Alert: Renflexis Medication Guide